Acute toxicity and withdrawal syndromes related to gamma‐hydroxybutyrate (GHB) and its analogues gamma‐butyrolactone (GBL) and 1,4‐butanediol (1,4‐BD) | Zendy

Wood David M. | Zendy; Brailsford Alan D. | Zendy; Dargan Paul I. | Zendy

Premium

Acute toxicity and withdrawal syndromes related to gamma‐hydroxybutyrate (GHB) and its analogues gamma‐butyrolactone (GBL) and 1,4‐butanediol (1,4‐BD)

Author(s) -

Wood David M.,

Brailsford Alan D.,

Dargan Paul I.

Publication year - 2011

Publication title -

drug testing and analysis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.065

H-Index - 54

eISSN - 1942-7611

pISSN - 1942-7603

DOI - 10.1002/dta.292

Subject(s) - gamma hydroxybutyrate , 1,4 butanediol , toxicity , acute toxicity , pharmacology , drug , medicine , chemistry , toxicology , biology , biochemistry , catalysis

Gamma‐hydroxybutyrate (GHB) has been used as a recreational drug since the 1990s and over the last few years there has been increasing use of its analogues gamma‐butyrolactone (GBL) and to a lesser extent 1,4‐butanediol (1,4BD). This review will summarize the literature on the pharmacology of these compounds; the patterns and management of acute toxicity associated with their use; and the clinical patterns of presentation and management of chronic dependency associated with GHB and its analogues. Copyright © 2011 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research